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Abstract  Introduction: Antiangiogenic agents are often administered for treatment of Branch Retinal Vein 
Occlusion (BRVO). Among them, Bevacizumab has noticeable antiangiogenic and antiedemigenic properties and 
possesses great capacity to penetrate the retinal tissue, particularly in pathological circumstances characterized by 
altered external or internal blood-retinal barrier.Bevacizumab has an optimal bio-efficacy based on inhibition of the 
activity of Vascular Endothelial Growth Factor (VEGF). Nonetheless, despite its efficacy, here we describe the 
adverse effects associated with intraocular injection of bevacizumab in a patient affected by retinal vein occlusion. 
Case presentation: We present a case report of an 11-year old Caucasian malesubject affected by BRVO in his left 
eye. The patient underwent an intra-vitreal (i.v.) injection of bevacizumab 100 (1.25 mg/0.05ml). After that, the 
patient was monitored over time through a series of analyses including Ocular Coherence Tomography, 
Fluorangiography, Bulbar Ultrasound, Angio MRI BCVA scores and Intra Ocular Pressure. Results: Immediately 
after the i.v. injection, the patient experienced a strong and relentless pain radiating from the left ocular orbit, caused 
by a serious and unexpected malignant glaucoma and phthisis bulbi. Furthermore, the patient did not show any sign 
of improvement in visual function in the follow-up and at last required an ophthalmic prosthesisas a result of a sub-
atrophic and hypotonic eyeball. Conclusion: This case report suggests that i.v. injections of anti-VEGFs should be 
considered with caution when treating central and branch vein occlusion, and are not free of complications in certain 
clinical cases. 
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1. Introduction 
Branch Retinal Vein Occlusion (BRVO) is the most 
frequent vascular pathology after diabetic retinopathy, 
with an incidence of about 2.14/1000 per year in the 
population over 40 [1,2].This condition is characterized 
byretinal ischemia, neo-vascularization, intra-retinal sector 
haemorrhages and macular edema (ME). This pathology 
causesan immediate loss of visual acuity due to a series of 
physiopathological events, such asreduced capillary 
perfusion(with consequent retinal hypoxia) and an 
increased hydrostatic pressure resulting in haemorrhage 
and exudation of fluid [3]. So far, the preferred treatment 
modality isthe laser photo-coagulation, althoughnew 
therapies based on intra-vitreal (i.v.) administration of 
anti-vascular endothelial growth factor (VEGF) and 
cortisone have been more recently introduced [4,5,6]. 
VEGF is the biggest angiogenic stimulus responsible 
for the development of anomalous blood vessels in retinal 
vascular pathologies [7]. It has been demonstrated that 
intra-vitreal VEGF levels are significantly increased after 
central retinal vein occlusion, and, in case of ischemia, 
this increase may lead to loss of tight junctions, vascular 
leakage and ultimately edema [8]. Accordingly, nowadays 
it is recognized that the use of anti-VEGFs may improve 
the state of retinal micro-circulation [9]. 
Bevacizumab, a full-length humanized monoclonal 
antibody, is a VEGF inhibitor initially used in the 
treatment of metastatic colon-rectal cancer [10], and 
successively adopted to treat neovascular retinaldiseases 
[11]. The mechanism of action of bevacizumab is different 
from that of other anti-angiogenic compounds. While 
pegaptanib and ranibizumab penetrate the retina and reach 
the choroid, bevacizumab penetrates directly into the 
choroid, thus closing anomalous blood vessels [12]. This 
medication (given i.v.) is currently in use for the treatment 
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of different pathologies, such as Choroidal Neo 
Vascularization (CNV) caused by Age related Macular 
degeneration (AMD) [13,14], central retinal vein 
occlusion (CVO) [15], Diabetic Macular Edema (DME) 
and proliferative diabetic retinopathy (PDR) [2]. Here we 
present a case of ocular complications in a patient affected 
by retinal vein occlusion and treated with intraocular 
injection of bevacizumab. 
2. Case Presentation 
In November 2013, a 11-years old patient with a 2-
months history of blurred and distorted vision in left eye 
(LE) was admitted to our observation unit. Amsler grid 
test showed metamorphopsia in the LE and normal 
findings in the right eye (RE).The examination of the 
anterior segment was normal, and intra-ocular pressure 
(IOP) was 16mmHg in both eyes. Best corrected visual 
acuity(BCVA) was 20/50 in the LE and 20/20 in the RE. 
Biomicroscopic examination of the ocular fundus 
revealed acentral retinal vein occlusion with macular 
edema, confirmed by optical coherence tomography 
(OCT), an alteration of the chorio-capillary barrier and 
epithelial pigment, and increased foveal thickness (FT) 
480 micron (Figure 1). 
 
Figure 1. Bulbar ultrasonograhy: Vitreous dis-homogeneity left eye 
(LE) > right eye (RE). 
LE: liquid type alterations of the retinal profile in the posterior pole with 
involvement of the macula and optic disc. Edema of the optic nerve 
sheath. 
A bulbar ultrasonograhy revealed a vitreous 
dyshomogeneity in the LE, with liquid type alterations of 
the retinal profile in the posterior pole, with involvement 
of the macula and optic disc. An edema of the optic nerve 
sheath was present, with no evidence for expansive 
pathologies at the orbital site. 
Fluorescein angiography (FA) showed a picture of 
BRVO of ischemic- hemorrhagic type, with hyper-
fluorescence of the optic disc in the LE (Figure 2, Figure 3). 
 
Figure 2. Ultrasonograhy orbital: Non evident expansive pathologies at 
the orbital site. Para-nasal sinuses well evident. RE: retina always on 
plane and acoustic wave of the optic nerve within standard limits 
 
Figure 3. Fluorescein angiography (FA): BRVO of the ischemic- 
hemorrhagic type. Hyper-fluorescence of the optic disc in the left eye 
(LE) and no alterations of the hemo-retinal barrier (HRB) in right eye 
(RE) 
The RE did not present alterations of the blood-retinal 
barrier (BRB), with retina always on plane and acoustic wave 
of the optic nerve within standards (Figure 2, Figure 3). 
Routine Blood tests showed the following altered 
values: alkaline phosphatase (283 IU/L, range 42-121 
IU/L); anisocytosis (RDW 18.5%, range 10-16%); 
hyperchromia and microcytosis (MCV 65 fl, range 80-100; 
MCH 19.4 pg, range 26-34 pg),and neutropenia (NEU% 
43.2, range 50-80%). Immunological tests, anti-viral 
antibodies, anti-Toxoplasma, and VDRL were all negative. 
2.1. Neurological Examination 
Brain and Angio MRI showed a normal appearance of 
internal carotid arteries and their principal intracranial 
afferents. There were no evident alterations in the 
vertebro-basilar region and a representation of the 
principal intra-cranial venous branches with normal limits. 
Fearing a possible thrombosis or onset of a carotid dural 
cavernous fistola, an arteriography was proposed to the 
patient’s parents, but they did not give consent to this 
diagnostic procedure. 
2.2. Initial Treatment 
With informed consent, the patient was initially treated 
with a symptomatic general therapy consisting of seleparine 
(2850UI/0.3ml 2 fl. subcutaneously), Prednisolone (25 
mg/day, os), acetazolamide (250 mg/day, os) specifically 
indicated in the treatment ocular hypertonus, gastric 
protectors (150 mg/day, os) and a food supplement (one 
tablet/day). 
2.3. Bevacizumab Intravitreal Injection and 
Follow-up Complications 
Not noticing any improvement in child’s condition, the 
parents decided to take him to another hospital where he 
was subjected to intravitreal injection (i.v.) of 
bevacizumab 100 (1.25mg/0.05ml) tohis LE. 
Few hours after the injection, the patient complainedan 
intense pain in the LE and was brought again to our 
attention. His IOPin his LE was now 64mmHg. The 
patient was immediately treated with endovenous mannitol 
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(250mg×2) (drop infusion), acetazolamide (250 mg os; 
three tablet/ day) and topical atropine. To reduce pain and 
congestion, steroids, timolol drops, and carbonic 
anhydrase inhibitors were also administered.  
After a week, the pain was still relentless and 
unbearable and his IOP was 52mmHg. Thus, to manage 
the painan elastomeric pump was implanted and used to 
administer ketorolac, initiallyat a dose of 90mg and 
successively 48 mg (2 mg/h × 24h). 
Moreover, 20 applications of cyclo photocoagulation 
with YAG- laser free running mode (5.5 J)in the inferior 
section of the eye-ball (2.5 mm from the limbus) were 
given. During this time, haloperidol (1 mg)and 
orphenadrine hydrochloride(50 mg)were prescribed to the 
patient because of his altered psycho-physical condition. 
A new bulbar ultrasonography was repeated in the LE. 
Amarked dyshomogeneity vitreous inflammation was 
found, together with signs of retinal detachment (RD)of 
papillary origin and involving the macula of all the 
temporal sector of the eye (Figure 4). FAG also showed 
evidence of peri-papillary hemorrhage in RE (Figure 5, 
Figure 6). 
 
Figure 4. Bulbar ultrasonograhy at 20 days from the acute events in the 
LE: Marked dis-homogeneity vitreous inflammation. Altered retinal 
profile for retinal detachment (RD) of papillary origin and involving the 
macula of all temporal sectors of the eye 
 
Figure 5. FAG showed evidence of peri-papillary hemorrhage in right 
eye (RE) 
After 1 and 2 months from the acute event, LE visual 
acuity (AV) had markedly worsened to hand motion (HM). 
Rubeosis iridis was present at objective examination and 
IOP was 44 mmHg. A diffuse edema retinal was present 
and barely investigable because of an endovitreal 
hemorrhage. This edema was principally located in the 
posterior pole of the fundus, which was lifted at 
ophthalmoscopic examination. Bulbar Ultrasound (Figure 7) 
produced pathological echoes in the vitreal chamber, 
attributable to endovitreal hemorrhage with a posterior 
detachment of the vitreous membranes. The retinal 
alteration in the posterior pole was associated to organized 
exudation and retinal detachment.  
 
Figure 6. FAG showed evidence of peri-papillary hemorrhage in the 
right eye (RE) 
 
Figure 7. Bulbar ultrasonograhy: Pathological echoes in the vitreal 
chamber attributable to endovitreal hemorrhage with a posterior 
detachment of the vitreous membranes, particularly in the superior 
section 
Four months after the acute event, LE IOP 
progressively diminished to 23 mmHg with a consequent 
reduction of pain. Nonetheless, the patient showed 
athalamia and massive neo-vascularization, possibly 
evolving in a bulbar phthisis. 
After one year, the patient required an ocular prosthesis, 
as a result of a subatrophy and hypotonic eyeball without 
signs of flogosis.  
3. Discussion 
Macular edema (ME) is the most frequent cause of loss 
of vision [1,2,3] and is generally treated with either focal 
photocoagulation [4,5] or, more recently, with i.v. 
triamcinolone [6]. However, laser photocoagulation 
causes an irreversible destruction of para-central retinal 
tissue and thus new treatment modalities have been 
developed.  
Anti-angiogenic drugs, like corticosteroids, 
ranibizumab, pegaptanib and bevacizumab, represent new 
treatment options for ME without causing tissue damage 
[9,16,17]. In particular, antiangiogenic drugs may be 
useful for reducing both edema and neo-vascularization in 
occlusive pathologies [9,12,15]. Among them, bevacizumab, 
 Neuro-Ophthalmology & Visual Neuroscience 25 
 
administered i.v., has become the reference treatment 
option for the cure of ocular occlusive pathologies [16,18]. 
When compared to the traditional laser therapy, 
bevacizumab has been shown to induce comparable and 
significant improvements in patients affected by ME 
secondary to branch retinal vein occlusion (BRVO), both 
with chronic [19] or acute i.v. administration [20,21]. 
In case of BVRO, the optimal treatment strategy is still 
matter of debate. Natarajan (22) states that, in the majority 
of cases of Central Vein Occlusion (CVO), the disease 
may undergo to spontaneous regression after 3 months. 
However, in the CVO case reported here, no improvement 
in BCVA and ME was observed. Therefore, after 20 days 
of retinal vein occlusion (RVO), the patient underwent a 
fluorangiography (FAG) in order to establish the more 
appropriated therapeutic approach [16]. Photocoagulation 
or laser therapy could not be adopted because ME was 
such extensive to limit their efficacy [18,24]. Thus, as the 
patient did not show any improvement in his visual 
function during time, his parents decided to subject him to 
i.v. injections of bevacizumab in another health institute. 
The bevacizumab i.v. injection did not improve his retinal 
condition, and on the contrary provoked a greater dilation 
and a entanglement of the retinal veins, also evidenced by 
the FAG [12]. 
The reason for this failure is not clear. Bevacizumab is 
a drug inhibiting the development of neovascularization 
by blocking the molecular pathways of VEGFs and on 
their pro-angiogenic input [11,12]. Although this 
pharmacological action has been shown to be beneficial in 
case of ocular occlusive pathologies, the physiopathological 
mechanisms underlying RVO [23,24] and the role of 
VEGFs in ME [25] remain to be determined. Experimental 
studies suggest that VEGFs may also play a protective 
role in the hemo-dynamics of the retina and even a direct 
retinal neuroprotective role, particularly in hypoxic 
conditions [18,25]. In a recent review by Manousaridis 
and Talks [26], it is evidenced that in case of venous 
occlusion VEGFs promote the restoration of venous flow 
through the formation of blood vessels and blood 
perfusion in retinal unperfused areas, thus preventing 
ischemic lesions in the retina [9,25]. In addition, studies 
performed in primates have shown that anti-VEGF 
treatment reduces chorio-capillary fenestrations of retinal 
endothelial cells, increasing the ischemic damage in the 
internal retina [3]. 
These studies suggest that the blockade of VEGF action 
in cases of significant is chaemia at baseline may be 
detrimental to the retinal circulation. Supporting this 
notion, it has been demonstrated that repeated injections 
of bevacizumab may cause harmful effects on neuronal 
viability of retinal ganglion cells in rats [27]. In humans, 
retinal detachment (retinal pigment epithelium RPE) has 
been reported in two patients after repeated bevacizumab 
injections [24] while in a study of 707 patients both 
systemic and local complications were reported, although 
in minimal percentages [17]. Systemic complications 
included cerebral infarct, elevated systolic pressure, skin 
rashes and irregular periods while the most commonlocal 
complications were corneal abrasions, lesions of the 
crystalline, inflammation, RPE detachment, and loss of 
vision [22]. These and other data have led to the 
suggestion that maintaining a normal balance between 
antiangiogenic and proangiogenic VEGFs (VEGF 
165/VEGF165b) would be a more suitable approach, 
instead of only targeting proangiogenic VEGFs 
[7,18,25,28]. However, it should be noted that in the 
present case report bevacizumab injection was performed 
in another health institute and consequently we lack 
necessary information on the accuracy of the procedure 
adopted or other possible complications risen during that 
period. 
4. Conclusions 
In conclusion, in the case report just presented, the 
decision to use i.v. bevacizumab injections did not prove 
to be the best choice as the results were dramatic. 
Ultimately, the patient was forced to adopt an ocular 
prosthesis because of the resultant phthisis. Although anti-
VEGF agents are used in the management of ME with 
retinal vein occlusion [25,26,29], we believe that these 
therapies should be considered with caution because of the 
insufficient knowledge of the physiopathological 
mechanisms by which they act in retinal occlusive 
pathologies. In addition, further studies are necessary to 
establish the optimal dose range in young patients, as 
compared to adults.  
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